| Trial ID: | L1765 |
| Source ID: | NCT05390307
|
| Associated Drug: |
Liraglutide / Semaglutide
|
| Title: |
Obesity Treatment to Improve Diabetes
|
| Acronym: |
OTID
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Liraglutide / Semaglutide|DRUG: Dapagliflozin|DRUG: Liraglutide or Semaglutide / Dapagliflozin|DRUG: Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|OTHER: Usual care
|
| Outcome Measures: |
Primary: Weight, Percentage change in total body weight, 26 weeks | Secondary: Glycaemia, Change in HbA1c, 26 weeks|Hypertension, Change in systolic and diastolic blood pressure, 26 weeks|Lipidaemia, Change in lipid profile, 26 weeks|Albuminuria, Change in albumin creatinine ratio, 26 weeks|Waist circumference, Change in waist circumference, 26 weeks|Weight change, Proportion of participants reaching total body weight loss of ≥5%, ≥10% and ≥15%, 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: Dasman Diabetes Institute
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-04-01
|
| Completion Date: |
2024-01-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-02-28
|
| Locations: |
Dasman Diabetes Institute, Kuwait City, Al Asimah, 15462, Kuwait
|
| URL: |
https://clinicaltrials.gov/show/NCT05390307
|
